We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HLIO:NYSEHelios Technologies, Inc. Analysis

Data as of 2026-04-08 - not real-time

$65.72

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Helios Technologies delivered a strong fourth‑quarter, posting $210.7 million in sales and $48.4 million in full‑year net income, while guiding FY 2026 revenue to $820‑$860 million and completing a 330,000‑share buyback. Revenue grew 17.4% YoY and the board announced a 33% increase in the quarterly dividend, underscoring confidence in cash‑flow generation.
On the technical side, the stock trades at $65.72, comfortably above the 20‑day SMA of $65.45 but below the 50‑day SMA of $68.60, with a bullish MACD crossover (histogram +0.25) and rising volume supporting short‑term upside toward the $69.18 resistance. The 30‑day volatility of ~41% and a beta of 1.34 signal heightened price swings, yet the current price sits near a solid $62.05 support level.
Valuation is mixed: a trailing PE of 45.3 versus the industry average of 29.6 suggests the stock is priced high, but the DCF fair value of $68.46 and a forward PE of 20.5 point to a fair valuation with roughly 21% upside to the consensus $79.5 target. Analyst sentiment is strongly positive ("strong_buy"), and the dividend yield of 0.73% with a 24.8% payout ratio appears sustainable given robust operating cash flow.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD crossover with positive histogram
  • Price above 20‑day SMA and near strong support
  • Recent earnings beat and share buyback supporting demand

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth of 17% and FY guidance indicating continued expansion
  • Analyst consensus target of $79.5 implying ~21% upside
  • Dividend increase and sustainable payout ratio

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • CORE 2030 strategic roadmap targeting higher‑margin solutions
  • Consistent free cash flow and manageable debt levels
  • Blend of growth prospects and dividend income for total return

Key Metrics & Analysis

Financial Health

Revenue Growth17.40%
Profit Margin5.77%
P/E Ratio45.3
ROE5.39%
ROA3.86%
Debt/Equity41.46
P/B Ratio2.3
Op. Cash Flow$127.3M
Free Cash Flow$93.5M
Industry P/E29.6

Technical Analysis

TrendNeutral
RSI47.9
Support$62.05
Resistance$69.18
MA 20$65.45
MA 50$68.60
MA 200$55.09
MACDBullish
VolumeIncreasing
Fear & Greed Index84.86

Valuation

Fair Value$68.46
Target Price$79.50
Upside/Downside20.97%
GradeFair
TypeBlend
Dividend Yield0.73%

Risk Assessment

Beta1.34
Volatility40.91%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.